Health
PharmAust continues to progress lead drug monepantel in treating canine and human cancers, COVID-19 – Small Caps
Six dogs have completed PharmAust’s (ASX: PAA) phase IIb trial evaluating its lead drug monepantel (MPL) in the most prevalent cancer in canines B-cell lymphoma….
Six dogs have completed PharmAusts (ASX: PAA) phase IIb trial evaluating its lead drug monepantel (MPL) in the most prevalent cancer in canines B-cell lymphoma.
During the March quarter, PharmAust revealed six dogs with stage four to five B-cell lymphoma had completed evaluation across five trial sites.
However, one dog was not in compliance with the trial process and was subsequently withdrawn.
PharmAust noted the remaining dogs side-effects were less than conventional anti-cancer drugs, with only…
-
General23 hours agoDeath of 86-year-old driver in Karoonda Highway crash prompts push for change
-
General20 hours agoTop chess player Magnus Carlsen forced into draw in historic game against over 134,000 people
-
Business19 hours agoIs Warren Buffett’s Berkshire Hathaway the smartest investment you can make today?
-
Noosa News23 hours agoStory Bridge documents released amid cover-up claims